Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Imatinib - Oral Drug: Imatinib- 600mg per oral once daily
(D1-D14)
Control Intervention1: supportive care: supportive care
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: a) Age -18 years and above (no upper age limit ) b) Mildly symptomatic Patients admitted in the AIIMS hospital with a proven diagnosis of COVID 19 infection on RT-PCR, with National Early Warning Score (NEWS score)
Exclusion criteria
Exclusion criteria: a) Abnormal Liver function at baseline, i.e. Serum Bilirubin > 1.5 ULN, ALT and AST > 3 ULN. Upto 5 times in case of chronic liver disease. b) Abnormal renal functions at baseline, i.e.. Serum creatinine > 1.5 ULN c) Prior history of exposure to imatinib d) Any other condition assessed by physiciansâ?? team that will lead to difficulty in carrying out the trial. e) Pregnant or breast feeding women. f) Patients unable to swallow oral medicines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients with negative viral titre in the intervention arm in comparison with those in standard arm on D-7 2. Proportion of patients with negative viral titre in the intervention arm in comparison with those in standard arm on D-14Timepoint: d-7 & d-14 | — |
Secondary
| Measure | Time frame |
|---|---|
| Docking studies for the drug will be done during the course of study.Timepoint: during the course of whole study;i) To investigate improvement in symptoms at D-3,D-7, D-10 & D-14 ii) To study duration of hospitalization, mechanical ventilation or death by day 28. iii) Safety analysis as per CTCAE version 5.0 Timepoint: Day -14 and Day-28 | — |
Countries
India
Contacts
Public ContactAkash Kumar
All India Institute of Medical Sciences
Outcome results
None listed